Shanghai SiniWest Pharmaceutical & Chemical Technology Co., Ltd. was established by SiniWest Holdings, Inc. (U.S.A.) in October 1994 as wholly owned foreign enterprise (WOFE). Its main business scope is to provide biopharmaceutical- and chemical-related technical services such as consultation, licensing, investment and product development.

　　With increasing uproar of "return to nature" in the international arena, natural medicine/nutraceutical market has experienced a huge expansion. The shortcomings of chemical drugs are gradually being understood by the public and attention being once again directed towards botanical drugs used for thousands of years. In recent years, natural medicine/nutraceutical market in the West is growing rapidly; consumption is increasing at an average rate of 16% per annum. At present, the annual global sales of natural medicines (including traditional drugs of different countries) has reached US$14.5 billion, of which one half was sold in the European market. China has a long history of using herbal medicines and possesses a collection of traditional medical practices and herb use. Over the years, TCM doctors have accumulated a wealth of clinical experience and developed numerous effective ancient recipes as well as newly approved formulae. Although China is a major botanical drug producer, it only occupies 3% of the world natural medicine trade volume, of which 65% are raw materials with low value and no more than 29% were exported to Western countries. The cause of this imbalance lies in obsolete technologies in plantation, processing and manufacturing that lead to poor production standards and unreliable product quality. If China wishes to find an appropriate place in the world natural medicine market, it must absorb advanced technologies, raise production standards, enhance product quality, and increase intrinsic value and profit margin.

　　To capture this business opportunity, Shanghai SiniWest Pharmaceutical & Chemical Technology Co., Ltd., in collaboration with Ancile Pharmaceuticals of U.S.A., has invested a significant amount of human and financial resources to establish a world-class research facility specializing in natural product chemistry. Its technical team is consisted of highly motivated, well-trained, experience-rich scientists of different levels who also have complementary expertise or skill sets. The strategy is to further develop certain TCM's with verified clinical efficacies by application of advanced technologies and enhanced quality standards. The end products would be more competitive in the marketplace. While the company is strengthening international cooperation and improving both hardware and software relative to infrastructure, it is heavily engaged in TCM and synthetic new drug research and development, preparation of natural product standards, and structure elucidation of impurities contained within drug substances to be exported.